Denali Therapeutics Inc. filings document regulatory, financial and governance disclosures for a biotechnology company developing blood-brain-barrier-crossing therapeutics. Recent 8-K reports record operating results, FDA approval and launch-related disclosures for AVLAYAH™, clinical pipeline updates, and material events tied to collaboration agreements and royalty funding arrangements.
Denali’s proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. Its event filings also describe capital-structure and financing obligations, Regulation FD disclosures, exhibit-based press releases, and formal updates on TransportVehicle-enabled programs across lysosomal storage and neurodegenerative disease indications.
Denali Therapeutics (DNLI) reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The company disclosed this under Item 2.02 and furnished the full press release as Exhibit 99.1.
The materials in Item 2.02 and Item 9.01 (including Exhibit 99.1) are designated as furnished, not filed, under the Exchange Act. The filing also lists the Inline XBRL cover page as Exhibit 104.
Denali Therapeutics (DNLI) reported that the FDA has extended the PDUFA action date for its Biologics License Application seeking accelerated approval of tividenofusp alfa to treat MPS II (Hunter syndrome). The decision date moved from January 5, 2026 to April 5, 2026.
According to the company, the FDA granted the extension to allow review of updated clinical pharmacological information, which was classified as a Major Amendment to the BLA. The update was furnished under Regulation FD, and a related press release was included as an exhibit.
Denali Therapeutics insider report: Ryan J. Watts, President and CEO and a director, reported transactions dated 09/03/2025. He made an in-kind charitable contribution of 50,000 shares of DNLI to a donor-advised fund, and the filing also shows a disposal of 253,071 shares. Following the reported transactions, the filing shows 2,152,604 shares beneficially owned indirectly through the Watts Family 2015 Trust (Watts serves as trustee). The filing notes that 177,940 of the holdings are unvested RSUs. The form was signed by a POA on 09/05/2025.
Denali Therapeutics insider sale to cover taxes; holdings after transaction detailed. Director and Chief Operating and Financial Officer Alexander O. Schuth sold 2,937 shares of Denali common stock on 08/12/2025 at a weighted average price between $13.35 and $13.58 per share to satisfy tax obligations from the settlement of previously vested restricted stock units. After the sale, Mr. Schuth beneficially owns 242,346 shares directly (including 128,405 unvested RSUs and 975 shares from an ESPP purchase) and 523,749 shares indirectly via The Schuth Family Trust, for which he is trustee.
Denali Therapeutics (DNLI) insider sale by Chief Medical Officer Carole Ho. The filing reports two open-market sales executed on 08/12/2025 and 08/13/2025 of a combined 3,743 shares, at weighted average prices ranging roughly from $13.34 to $14.64 per share, to satisfy tax obligations related to the settlement of previously vested restricted stock units. After the transactions, the reporting person directly beneficially owned 216,585 shares. The filing also discloses indirect holdings of 183,219 shares held by the Rohatgi-Ho Family 2009 Revocable Trust and 25,000 shares held by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the reporting person’s children. The sales on 08/12/2025 were S-code disposals with a weighted average reported sale price up to $13.58 and were effected pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024.
Denali Therapeutics (DNLI) reported a Form 144 notice showing an intended sale of 806 shares of common stock, representing restricted stock units acquired on 08/11/2025. The aggregate market value of the proposed sale is $10,655.32, with an approximate sale date of 08/13/2025 on NASDAQ through Morgan Stanley Smith Barney.
The filing also discloses a sale earlier in the three‑month window by Carole Ho of 2,937 shares on 08/12/2025 for gross proceeds of $39,880.52. The notice includes the standard representation that the seller does not possess undisclosed material information about the issuer.
Denali Therapeutics reported a proposed sale of 2,937 common shares acquired on 08/11/2025 through a restricted stock lapse as equity compensation. The filing lists the aggregate market value as $39,876.18 and shows 146,419,263 shares outstanding. The sale is planned to occur approximately on 08/12/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filer reports "Nothing to Report" for securities sold in the past three months and includes the standard attestation that they do not possess undisclosed material adverse information.
Denali Therapeutics Inc. has submitted a Form 144 notifying a proposed sale of 2,937 common shares with an aggregate market value of $39,875.82. The shares were acquired on 08/11/2025 due to a restricted stock lapse as equity compensation, and the filing lists an approximate sale date of 08/12/2025. The transaction is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares represent roughly 0.002% of the issuer's reported 146,419,263 shares outstanding. The filer reports Nothing to Report for securities sold in the past three months. This notice is a routine disclosure of intent to sell vested equity and contains no additional material items beyond the transaction details provided.
Denali Therapeutics (DNLI) is reported to be held by Wellington entities with an aggregate beneficial ownership of 5,664,733 shares, representing 3.9% of the outstanding common stock. The cover pages show no sole voting or dispositive power and report shared voting power of 5,456,035 and shared dispositive power of 5,664,733.
The securities are owned of record by clients of Wellington’s investment advisers and the filing includes a certification that the holdings were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
Denali reported a net loss of $124.1 million for the three months and $257.1 million for the six months ended June 30, 2025, driven by higher research and development and G&A expenses. Research and development spending was $102.7 million for the quarter and $218.9 million year-to-date, including increased TV-platform and manufacturing-related costs tied to the new Salt Lake City facility.
Liquidity remains substantial with $977.4 million in cash, cash equivalents and marketable securities as of June 30, 2025, and short-term marketable securities concentrated in U.S. treasuries. Key operational milestones include Breakthrough Therapy designation and a Priority Review acceptance for tividenofusp alfa (DNL310) with a PDUFA target action date of January 5, 2026, regulatory alignment that cerebrospinal fluid heparan sulfate may support accelerated approval for DNL126, and the March 2025 opening of a clinical biomanufacturing facility.
The company disclosed several collaboration changes: Sanofi’s license to CNS products and Takeda’s ATV:TREM2 collaboration were terminated (no future milestones expected for those programs), and the 2024 divestiture of certain small molecule programs produced a non-cash gain and a retained equity investment in Tenvie. Total assets declined to $1.166 billion and stockholders’ equity to $1.027 billion as of June 30, 2025.